메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
한국병원약사회 병원약사회지 병원약사회지 제34권 제2호
발행연도
2017.1
수록면
200 - 210 (11page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background : ABO incompatible (ABOi) kidney transplantation has become an effective option to resolve organ shortage. In Korea, in 2015, the number of patients who received kidney transplantation was 1,891; among them, the number of ABOi kidney transplantation was 450. To ensure successful ABOi kidney transplantation, rituximab is used to reduce acute antibody-mediated rejection (AMR). However, the adequate rituximab dosage in ABOi kidney transplantation remains undetermined; therefore, this study aimed to evaluate the effective dose of rituximab. Methods : From July 2012 to June 2015, we conducted a chart review in a total of 53 ABOi kidney transplantation recipients, who took rituximab before the transplantation at Severance Hospital. The immunosuppressive protocol consisted of tacrolimus, mycophenolate mofetil, and corticosteroids. The pre-conditioning protocol included double-filtration plasmapheresis and a single dose of rituximab. We classified the study population into two groups, i.e., the high dose rituximab group (375 mg/m2 rituximab, n=27) and the low dose rituximab group (200 mg/body rituximab, n=26). Information on the incidence of AMR, infection and neutropenia, reduction of anti A/B antibody titer, peripheral CD19 and CD20 levels, and population characteristic were collected from the medical records. Results : The incidence of AMR was 7.4% in the high dose rituximab group vs. 15.4% in the low dose rituximab group (P=0.42). Effective reduction of the anti A/B antibody titer and elimination of the peripheral blood CD19 and CD20 levels were observed in both groups. However, the infectious complications and incidence of late onset neutropenia (LON) were more common in the high dose rituximab group (29.6% vs. 15.4%, P=0.22; 40.7% vs. 0.0%, P 0.001). Conclusion : The results were similar in patients in the low dose rituximab group as compared to patients in the high dose rituximab group. These results suggested that the low dose of rituximab(200 mg/body) is sufficient in cases with ABOi kidney transplantation.

목차

등록된 정보가 없습니다.

참고문헌 (14)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0